STOCKHOLM, May 27, 2019 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) announces that the company will
participate at the Redeye Pre-ASCO Seminar in Stockholm. The presentation will take place at
9.15am on Tuesday, May 28, 2019. Dr.
Uli Hacksell, CEO of Medivir, will present the latest development
and the company´s future.
The presentation will be available via Medivirs website;
www.medivir.com.
For further information, please contact:
Uli Hacksell
CEO, Medivir AB
mobile: +46(0)73-125-0615.
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development as well as the
commercialization is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's
Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-to-present-at-the-redeye-pre-asco-seminar-on-may-28,c2825705
The following files are available for download:
|
https://mb.cision.com/Main/652/2825705/1052303.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivir-to-present-at-the-redeye-pre-asco-seminar-on-may-28-300856941.html
SOURCE Medivir
